**Core Concept**
Myasthenia gravis is an autoimmune disorder characterized by weakness and rapid fatigue of the muscles under voluntary control. It is caused by a defect in the conduction of nerve impulses to muscles due to **autoantibodies** against components of the **neuromuscular junction**. The underlying principle involves the disruption of normal **neurotransmission**.

**Why the Correct Answer is Right**
The correct answer involves antibodies against the **nicotinic acetylcholine receptor (AChR)**, which is the most common cause of myasthenia gravis. These antibodies lead to the destruction and downregulation of AChR, reducing the number of available receptors for acetylcholine to bind, thus impairing **neuromuscular transmission**. This results in muscle weakness and fatigue.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while other antibodies can be involved in myasthenia gravis, they are less common.
**Option B:** Incorrect as it does not directly relate to the primary pathophysiological mechanism of myasthenia gravis.
**Option C:** Incorrect because, although involved in neuromuscular junction function, it is not the primary target in myasthenia gravis.
**Option D:** Incorrect as it is not directly associated with the disease's primary autoimmune mechanism.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that myasthenia gravis can be effectively managed with medications that increase the amount of acetylcholine available to bind to the remaining AChR, such as **acetylcholinesterase inhibitors**.

**Correct Answer:** D. nicotinic acetylcholine receptor